News Breaks |
|
|
| January 23, 2013 |
| 13:45 EDT |  | BAYRY, BAYRY, BAYRY, CELG, CELG, CELG, LLY, LLY, LLY, ONXX, ONXX, ONXX, REGN, REGN, REGN, SNY, SNY, SNY | Leerink's biotech analyst hosts a luncheon meeting
Biotech Analyst Liang discusses the ongoing ASCO GI Cancer Symposium, physician impressions of the new Phase 3 data on CELG’s Abraxane and LLY’s Ramucirumab, as well as market dynamics for new agents in colorectal cancer such as Zaltrap and Stivarga at a Luncheon Meeting being held in San Francisco on January 25 at 2 pm. |
|
|
News For BAYRY;CELG;LLY;ONXX;REGN;SNY From The Last 14 Days Check below for free stories on BAYRY;CELG;LLY;ONXX;REGN;SNY the last two weeks. |
|
|
| June 18, 2013 |
| 11:52 EDT |  | REGN | Stocks with call strike movement; REGN MU
 Subscribe for More Information |
|
| 10:17 EDT | | LLY | Lilly puts active on FDA says investigating two deaths after Zyprexa injections
Subscribe for More Information |
|
| 10:12 EDT |  | LLY | FDA investigating two deaths of patients taking Lilly's Zyprexa
The FDA said in a safety announcement on its website that it is investigating two unexplained deaths in patients who received an intramuscular injection of the antipsychotic drug Zyprexa. The patients died 3-4 days after receiving an appropriate dose of the drug, well after the 3-hour post-injection monitoring period required under the Zyprexa Risk Evaluation and Mitigation Strategy, the agency said. Both patients were found to have very high olanzapine blood levels after death. Eli Lilly is the maker of Zyprexa. |
|
| 08:38 EDT | | SNY | Sanofi management to meet with JPMorgan
Subscribe for More Information |
|
| 08:36 EDT |  | REGN | Elan shares could be worh $19 in a buyout, says Jefferies
Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. |
|
| 07:22 EDT | | BAYRY | Citigroup to host a conference
Subscribe for More Information |
|
| June 17, 2013 |
| 11:34 EDT | | LLY | Eli Lilly: LIVALO 4mg has neutral effects on fasting serum glucose levels
Kowa Pharmaceuticals America and Eli Lilly and Company announced results of a pre-specified safety analysis from the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) trial evaluating the effect of LIVALO 4 mg compared with pravastatin 40 mg on changes in levels of blood glucose and glycated hemoglobin in HIV-infected adults with dyslipidemia. INTREPID was a Phase 4, multicenter, 12-week randomized superiority study followed by a 40-week safety extension study comparing the lipid-lowering effects of pitavastatin 4 mg and pravastatin 40 mg in adults with HIV infection and dyslipidemia. The results of this pre-specified safety analysis, presented yesterday at the Endocrine Society's 95th Annual Meeting & Expo in San Francisco, CA, showed neutral effects of pitavastatin 4 mg and pravastatin 40 mg on fasting serum glucose and HbA1c levels over 12 weeks. |
|
| 11:17 EDT | | LLY | Eli Lilly to host conference call
Subscribe for More Information |
|
| 06:06 EDT | | LLY | Transition Therapeutics announces exercise of TT-401 rights by Eli Lilly
Transition Therapeutics (TTHI) announced that Eli Lilly (LLY) has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401. In conjunction with this assumption of rights, Transition will receive a $7M milestone payment. Lilly and Transition have amended their agreement to address future development of TT-401 and associated financial arrangements. Lilly will assume all costs and perform all future development and commercialization activities of TT-401. Transition will contribute payment of $14M to Lilly in three separate installments during the Phase 2 clinical study. If TT-401 is successfully commercialized, Transition will be eligible to receive approximately $240M in additional milestone payments. Transition will also be eligible to receive a double-digit royalty on sales of TT-401 products and a low single digit royalty on related compounds. |
|
| 05:44 EDT | | CELG | Celgene awarded marketing authorisation for Revlimid from EC
Subscribe for More Information |
| |
| June 14, 2013 |
| 08:23 EDT | | CELG | Celgene multiple likely to expand further, says Cantor
Cantor believes that Celgene is in the process of diversifying its revenue as it introduces new products. The firm has an upbeat outlook on the company's Apremilast drug and keeps a Buy rating on the stock. |
|
| 06:07 EDT | | CELG | Celgene achieves statistical significance for endpoints in Behcet trial
Subscribe for More Information |
|
| June 13, 2013 |
| 16:45 EDT | | LLY | Eli Lilly terminates Phase II study for beta secretase inhibitor
Subscribe for More Information |
|
| 14:36 EDT | | LLY | Lilly, Boehringer Ingelheim support ADA call for review of incretin therapies
Subscribe for More Information |
|
| 14:33 EDT | | LLY | Eli Lilly July volatility elevated into diabetes business update
Subscribe for More Information |
|
| 11:02 EDT | | SNY | Leerink's major pharma analyst holds an analyst/Industry conference call
Subscribe for More Information |
|
| 10:15 EDT | | CELG | Celgene management to meet with Jefferies
Subscribe for More Information |
|
| 10:14 EDT | | CELG | Celgene management to meet with Guggenheim
Subscribe for More Information |
|
| 10:05 EDT |  | CELG | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:03 EDT | | CELG | Celgene should continue to be bought, says RW Baird
Baird continues to be buyers of Celgene citing its new $3B share repurchase program and the publication of new trial data for apremilast's PALACE-1 efficacy. Shares are Outperform rated with a $130 price target. |
| |
|
|
|
|
